Wyeth R&D Pipeline Is 75% NMEs; Two Launches Per Year Will Start In 2006
Executive Summary
Three-quarters of the projects in Wyeth's research and development pipeline are new molecular entities, Wyeth Research President Robert Ruffolo, PhD, said during the company's R&D day in New York June 2
You may also be interested in...
Wyeth Shifting R&D Funds To Early-Stage Compound Research And Licensing
Wyeth is moving R&D spend from Phase III projects to discovery and early stage programs in an effort to continue meeting its goal of submitting two NDAs for new molecular entities per year, R&D President Robert Ruffolo said
Wyeth Shifting R&D Funds To Early-Stage Compound Research And Licensing
Wyeth is moving R&D spend from Phase III projects to discovery and early stage programs in an effort to continue meeting its goal of submitting two NDAs for new molecular entities per year, R&D President Robert Ruffolo said
Wyeth R&D Shifts Focus To New Products, Away From Lifecycle Management
Wyeth is shifting R&D spending away from lifecycle management, Exec VP-Pharmaceutical R&D Robert Ruffolor said